Lymphotactin enhances the in-vitro immune efficacy of dendritoma formed by dendritic cells and mouse hepatocellular carcinoma cells.

Journal of Zhejiang University. Science Pub Date : 2004-10-01 DOI:10.1631/jzus.2004.1255

Hao Zhang, Guo-ping Jiang, Shu-sen Zheng, Li-hua Wu, Feng Zhu, Zhen-lin Yang

{"title":"Lymphotactin enhances the in-vitro immune efficacy of dendritoma formed by dendritic cells and mouse hepatocellular carcinoma cells.","authors":"Hao Zhang, Guo-ping Jiang, Shu-sen Zheng, Li-hua Wu, Feng Zhu, Zhen-lin Yang","doi":"10.1631/jzus.2004.1255","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the in-vitro antitumor immune responses of dendritoma formed by mouse hepatocellular carcinoma (HCC) cells and lymphotactin (Lptn) gene modified dendritic cells (DCs).Method: DCs prepared from mouse bone marrow were genetically modified by lymphotactin adenovirus, and fused with H22 cells by polyethylene glycol (PEG). RT-PCR and ELISA were employed to identify lymphotactin expression at mRNA and protein level. Cell phenotypes and fusion efficiency was detected by FACS. The stimulatory effect of DC on T cells was detected by mixed lymphocyte reaction. The cytotoxicity activity against H22 cells was assayed by LDH method.Results: Lymphotactin could be efficiently expressed by DCLptn/H22 hybridoma. DCLptn/H22 cells could induce potent T cell proliferation effect and generate strong cytotoxic T lymphocyte (CTL) reaction against allogenic H22 cells.Conclusion: Lymphotactin genetic modification could enhance the in vitro immune activity of the dendritoma.","PeriodicalId":85042,"journal":{"name":"Journal of Zhejiang University. Science","volume":"5 10","pages":"1255-61"},"PeriodicalIF":0.0000,"publicationDate":"2004-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1631/jzus.2004.1255","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Zhejiang University. Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1631/jzus.2004.1255","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Objective: To investigate the in-vitro antitumor immune responses of dendritoma formed by mouse hepatocellular carcinoma (HCC) cells and lymphotactin (Lptn) gene modified dendritic cells (DCs).

Method: DCs prepared from mouse bone marrow were genetically modified by lymphotactin adenovirus, and fused with H22 cells by polyethylene glycol (PEG). RT-PCR and ELISA were employed to identify lymphotactin expression at mRNA and protein level. Cell phenotypes and fusion efficiency was detected by FACS. The stimulatory effect of DC on T cells was detected by mixed lymphocyte reaction. The cytotoxicity activity against H22 cells was assayed by LDH method.

Results: Lymphotactin could be efficiently expressed by DCLptn/H22 hybridoma. DCLptn/H22 cells could induce potent T cell proliferation effect and generate strong cytotoxic T lymphocyte (CTL) reaction against allogenic H22 cells.

Conclusion: Lymphotactin genetic modification could enhance the in vitro immune activity of the dendritoma.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

淋巴趋动素增强树突状细胞形成的树突瘤和小鼠肝癌细胞的体外免疫效果。

目的:探讨小鼠肝细胞癌(HCC)细胞与淋巴趋动素(Lptn)基因修饰的树突状细胞(dc)形成的树突状瘤的体外抗肿瘤免疫应答。方法:用淋巴趋动腺病毒对小鼠骨髓制备的树突状细胞进行基因修饰，用聚乙二醇(PEG)与H22细胞融合。RT-PCR和ELISA检测淋巴趋化素在mRNA和蛋白水平上的表达。用流式细胞仪检测细胞表型和融合效率。通过混合淋巴细胞反应检测DC对T细胞的刺激作用。LDH法检测其对H22细胞的细胞毒活性。结果:DCLptn/H22杂交瘤能高效表达淋巴蛋白。DCLptn/H22细胞能诱导T细胞增殖，对同种异体H22细胞产生强烈的细胞毒性T淋巴细胞(CTL)反应。结论:淋巴趋化素基因修饰可提高树突瘤的体外免疫活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Zhejiang University. Science

自引率

0.00%

发文量